Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Erlotinib products are in shortage in Canada (3 of 14 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jun 30, 2027.
A targeted cancer therapy (EGFR inhibitor) used to treat lung and pancreatic cancer.
Products affected
3 / 14
In shortage since
Dec 1, 2020
Est. full return
Jun 30, 2027
Reports on file
19
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
NAT-ERLOTINIB
150MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02483939 · since Dec 1, 2020, est. end Jun 30, 2027 · Long Term Back order
Active shortage
NAT-ERLOTINIB
100MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02483920 · since Dec 1, 2020, est. end Jun 30, 2027 · Long term back order
Active shortage
NAT-ERLOTINIB
25MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02483912 · since Dec 1, 2020, est. end Jun 30, 2027 · Long Term Backorder
Resolved
TEVA-ERLOTINIB
150MG · TABLET · TEVA CANADA LIMITED
DIN 02377713 · ended Mar 4, 2026 · Disruption of the manufacture of the drug.
Discontinued
TARCEVA
25MG · TABLET · HOFFMANN-LA ROCHE LIMITED
DIN 02269007
Discontinued
TARCEVA
100MG · TABLET · HOFFMANN-LA ROCHE LIMITED
DIN 02269015
Discontinued
TARCEVA
150MG · TABLET · HOFFMANN-LA ROCHE LIMITED
DIN 02269023
Resolved
TEVA-ERLOTINIB
100MG · TABLET · TEVA CANADA LIMITED
DIN 02377705 · ended Aug 7, 2024 · Disruption of the manufacture of the drug.
Resolved
TEVA-ERLOTINIB
25MG · TABLET · TEVA CANADA LIMITED
DIN 02377691 · ended Jul 30, 2024 · Disruption of the manufacture of the drug.
Resolved
TEVA-ERLOTINIB
150MG · TABLET · TEVA CANADA LIMITED
DIN 02377713 · ended Apr 27, 2023 · Disruption of the manufacture of the drug.
Discontinued
PMS-ERLOTINIB
150MG · TABLET · PHARMASCIENCE INC
DIN 02454394
Discontinued
PMS-ERLOTINIB
100MG · TABLET · PHARMASCIENCE INC
DIN 02454386
Showing 12 of 19 reports. All reports are on file with Health Canada.
What's happening
Erlotinib is currently affected by 3 active shortage reports filed with Health Canada by NATCO PHARMA (CANADA) INC.
The reported causes are: long term back order; long term back order; long term backorder. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Erlotinib is classified under “OTHER ANTINEOPLASTIC AGENTS” (ATC L01XE).
Recent changes
No changes recorded yet.
Common questions
What is Erlotinib used for?
A targeted cancer therapy (EGFR inhibitor) used to treat lung and pancreatic cancer.
When will Erlotinib be back in stock in Canada?
The latest manufacturer estimate is Jun 30, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Erlotinib in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.